Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 605

1.

Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer.

Chen D, Menon H, Verma V, Seyedin SN, Ajani JA, Hofstetter WL, Nguyen QN, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Barsoumian HB, Erasmus JJ, Lee JH, Bhutani MS, Hess KR, Minsky BD, Welsh JW.

JAMA Oncol. 2019 Sep 17. doi: 10.1001/jamaoncol.2019.2809. [Epub ahead of print]

PMID:
31529018
2.

Ushering in Liquid Biopsy for the Microsatellite Status: Advantages and Caveats.

Wang L, Ajani JA.

Clin Cancer Res. 2019 Sep 16. pii: clincanres.2585.2019. doi: 10.1158/1078-0432.CCR-19-2585. [Epub ahead of print]

PMID:
31527165
3.

Gastric cancer in the remnant stomach after pancreaticoduodenectomy: A case series.

Sonoda K, Samdani RT, Ikoma N, Kaya DM, Blum-Murphy M, Ajani JA, Badgwell BD, Katz MH, Rashid A, Estrella JS.

J Surg Oncol. 2019 Sep 9. doi: 10.1002/jso.25695. [Epub ahead of print]

PMID:
31498442
4.

Taxane- Versus Cisplatin-Based Chemotherapy With Radiation Therapy Is a Better Platform to Refine Esophageal Cancer Therapy.

Rogers JE, Ajani JA.

J Clin Oncol. 2019 Aug 29:JCO1901247. doi: 10.1200/JCO.19.01247. [Epub ahead of print] No abstract available.

PMID:
31465257
5.

Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer.

Yamashita K, Iwatsuki M, Harada K, Eto K, Hiyoshi Y, Ishimoto T, Nagai Y, Iwagami S, Miyamoto Y, Yoshida N, Komohara Y, Ajani JA, Baba H.

Gastric Cancer. 2019 Aug 26. doi: 10.1007/s10120-019-00999-9. [Epub ahead of print]

PMID:
31451991
6.

Targeting CDK9 and MCL-1 by a new CDK9/p-TEFb inhibitor with and without 5-fluorouracil in esophageal adenocarcinoma.

Tong Z, Mejia A, Veeranki O, Verma A, Correa AM, Dokey R, Patel V, Solis LM, Mino B, Kathkuda R, Rodriguez-Canales J, Lin SH, Krishnan S, Kopetz S, Blum M, Ajani JA, Hofstetter WL, Maru DM.

Ther Adv Med Oncol. 2019 Jul 25;11:1758835919864850. doi: 10.1177/1758835919864850. eCollection 2019.

7.

Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy.

Stark AP, Ikoma N, Chiang YJ, Estrella JS, Das P, Minsky BD, Blum MM, Ajani JA, Mansfield P, Badgwell BD.

Ann Surg Oncol. 2019 Oct;26(11):3602-3610. doi: 10.1245/s10434-019-07638-8. Epub 2019 Jul 26.

PMID:
31350645
8.

Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, Denlinger CS, Enzinger PC, Fanta P, Farjah F, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Leong S, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Paluri RK, Park H, Perry KA, Pimiento J, Poultsides GA, Roses R, Strong VE, Wiesner G, Willett CG, Wright CD, McMillian NR, Pluchino LA.

J Natl Compr Canc Netw. 2019 Jul 1;17(7):855-883. doi: 10.6004/jnccn.2019.0033.

PMID:
31319389
9.

Morbidity following salvage esophagectomy for squamous cell carcinoma: the MD Anderson experience.

Mitchell KG, Nelson DB, Corsini EM, Vaporciyan AA, Antonoff MB, Mehran RJ, Rice DC, Roth JA, Sepesi B, Walsh GL, Bhutani MS, Maru DM, Wu CC, Nguyen QN, Ajani JA, Swisher SG, Hofstetter WL.

Dis Esophagus. 2019 Jul 17. pii: doz067. doi: 10.1093/dote/doz067. [Epub ahead of print]

PMID:
31313820
10.

Can PD-L1 expression evaluated by biopsy sample accurately reflect its expression in the whole tumour in gastric cancer?

Yamashita K, Iwatsuki M, Harada K, Koga Y, Kiyozumi Y, Eto K, Hiyoshi Y, Ishimoto T, Iwagami S, Baba Y, Miyamoto Y, Yoshida N, Komohara Y, Ajani JA, Baba H.

Br J Cancer. 2019 Jul;121(3):278-280. doi: 10.1038/s41416-019-0515-5. Epub 2019 Jul 9.

PMID:
31285589
11.

Meta-Enrichment Analyses to Identify Advanced Gastric Cancer Patients Who Achieve a Higher Response to S-1/Cisplatin.

Takeuchi M, Ajani JA, Fang X, Pfeiffer P, Takeuchi M, van Laarhoven HWM.

Cancers (Basel). 2019 Jun 21;11(6). pii: E871. doi: 10.3390/cancers11060871.

12.

Frequency and Implications of Paratracheal Lymph Node Metastases in Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma.

Harada K, Hwang H, Wang X, Abdelhakeem A, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Zhao M, Bhutani MS, Nguyen QN, Swisher SG, Ikoma N, Badgwell BD, Hofstetter WL, Ajani JA.

Ann Surg. 2019 Jun 7. doi: 10.1097/SLA.0000000000003383. [Epub ahead of print]

PMID:
31188215
13.

Endoscopic resection for esophageal or gastroesophageal junction adenocarcinoma.

Harada K, Zhao M, Baba H, Ajani JA.

Dig Med Res. 2019 Apr;2. pii: 7. doi: 10.21037/dmr.2019.04.01. Epub 2019 Apr 22. No abstract available.

14.

Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response.

Wang R, Song S, Harada K, Ghazanfari Amlashi F, Badgwell B, Pizzi MP, Xu Y, Zhao W, Dong X, Jin J, Wang Y, Scott A, Ma L, Huo L, Vicente D, Blum Murphy M, Shanbhag N, Tatlonghari G, Thomas I, Rogers J, Kobayashi M, Vykoukal J, Estrella JS, Roy-Chowdhuri S, Han G, Zhang S, Mao X, Song X, Zhang J, Gu J, Johnson RL, Calin GA, Peng G, Lee JS, Hanash SM, Futreal A, Wang Z, Wang L, Ajani JA.

Gut. 2019 Jun 6. pii: gutjnl-2018-318070. doi: 10.1136/gutjnl-2018-318070. [Epub ahead of print]

15.

The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer.

Yin Y, Liu W, Shen Q, Zhang P, Wang L, Tao R, Li H, Ma X, Zeng X, Cheong JH, Song S, Ajani JA, Mills GB, Tao K, Peng G.

Mol Cancer Ther. 2019 Aug;18(8):1439-1450. doi: 10.1158/1535-7163.MCT-18-0833. Epub 2019 May 29.

PMID:
31142662
16.

Ramucirumab and Paclitaxel Administered Every 2 Weeks (mRAINBOW Regimen) in Advanced Gastroesophageal Adenocarcinoma.

Rogers JE, Xiao L, Amlashi FG, Elimova E, Blum Murphy MA, Sanders E, Shanbhag N, Thomas I, Ajani JA.

Oncology. 2019;96(5):252-258. doi: 10.1159/000496978. Epub 2019 Mar 20.

PMID:
30893708
17.

The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors.

Koga Y, Iwatsuki M, Yamashita K, Kiyozumi Y, Kurashige J, Masuda T, Eto K, Iwagami S, Harada K, Ishimoto T, Baba Y, Yoshida N, Miyanari N, Takamori H, Ajani JA, Baba H.

Gastric Cancer. 2019 Mar 11. doi: 10.1007/s10120-019-00950-y. [Epub ahead of print]

PMID:
30854619
18.

SOURCE: A Registry-Based Prediction Model for Overall Survival in Patients with Metastatic Oesophageal or Gastric Cancer.

van den Boorn HG, Abu-Hanna A, Ter Veer E, van Kleef JJ, Lordick F, Stahl M, Ajani JA, Guimbaud R, Park SH, Dutton SJ, Bang YJ, Boku N, Mohammad NH, Sprangers MAG, Verhoeven RHA, Zwinderman AH, van Oijen MGH, van Laarhoven HWM.

Cancers (Basel). 2019 Feb 5;11(2). pii: E187. doi: 10.3390/cancers11020187.

19.

Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation.

Harada K, Wu CC, Wang X, Mizrak Kaya D, Amlashi FG, Iwatsuki M, Blum Murphy MA, Maru DM, Weston B, Lee JH, Rogers JE, Thomas I, Shanbhag N, Bhutani MS, Hofstetter WL, Nguyen QN, Ajani JA.

Ann Surg. 2019 Jan 31. doi: 10.1097/SLA.0000000000003228. [Epub ahead of print]

PMID:
30720506
20.

Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.

Shah MA, Kang YK, Thuss-Patience PC, Ohtsu A, Ajani JA, Van Cutsem E, Hoersch S, Harle-Yge ML, de Haas SL.

Gastric Cancer. 2019 Jul;22(4):803-816. doi: 10.1007/s10120-018-00923-7. Epub 2019 Jan 31.

PMID:
30706247
21.

Higher rate of colon polyp detection aided by an artificial intelligent software.

Iwatsuki M, Harada K, Baba H, Ajani JA.

Transl Gastroenterol Hepatol. 2018 Dec 24;3:106. doi: 10.21037/tgh.2018.12.05. eCollection 2018. No abstract available.

22.

Neoadjuvant and adjuvant therapy for gastrointestinal stromal tumors.

Iwatsuki M, Harada K, Iwagami S, Eto K, Ishimoto T, Baba Y, Yoshida N, Ajani JA, Baba H.

Ann Gastroenterol Surg. 2018 Sep 27;3(1):43-49. doi: 10.1002/ags3.12211. eCollection 2019 Jan. Review.

23.

Laparoscopic Hyperthermic Intraperitoneal Chemotherapy is Safe for Patients with Peritoneal Metastases from Gastric Cancer and May Lead to Gastrectomy.

Newhook TE, Agnes A, Blum M, Estrella JS, Das P, Ho L, Ajani JA, Minsky BD, Mansfield P, Badgwell BD.

Ann Surg Oncol. 2019 May;26(5):1394-1400. doi: 10.1245/s10434-018-07140-7. Epub 2019 Jan 24.

PMID:
30680477
24.

Targeting Angiogenesis in Colorectal Carcinoma.

Lopez A, Harada K, Vasilakopoulou M, Shanbhag N, Ajani JA.

Drugs. 2019 Jan;79(1):63-74. doi: 10.1007/s40265-018-1037-9. Review.

PMID:
30617958
25.

A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer.

Bang YJ, Kang YK, Ng M, Chung HC, Wainberg ZA, Gendreau S, Chan WY, Xu N, Maslyar D, Meng R, Chau I, Ajani JA.

Eur J Cancer. 2019 Feb;108:17-24. doi: 10.1016/j.ejca.2018.11.017. Epub 2018 Dec 25.

PMID:
30592991
26.

YAP1-Mediated CDK6 Activation Confers Radiation Resistance in Esophageal Cancer - Rationale for the Combination of YAP1 and CDK4/6 Inhibitors in Esophageal Cancer.

Li F, Xu Y, Liu B, Singh PK, Zhao W, Jin J, Han G, Scott AW, Dong X, Huo L, Ma L, Pizzi MP, Wang Y, Li Y, Harada K, Xie M, Skinner HD, Ding S, Wang L, Krishnan S, Johnson RL, Song S, Ajani JA.

Clin Cancer Res. 2019 Apr 1;25(7):2264-2277. doi: 10.1158/1078-0432.CCR-18-1029. Epub 2018 Dec 18.

PMID:
30563933
27.

Cancer stem cells in esophageal cancer and response to therapy.

Harada K, Pool Pizzi M, Baba H, Shanbhag ND, Song S, Ajani JA.

Cancer. 2018 Oct 15;124(20):3962-3964. doi: 10.1002/cncr.31697. Epub 2018 Oct 25. No abstract available.

PMID:
30368777
28.

A balancing act: dual immune-checkpoint inhibition for oesophagogastric cancer.

Harada K, Abdelhakeem AAF, Ajani JA.

Nat Rev Clin Oncol. 2019 Jan;16(1):9-10. doi: 10.1038/s41571-018-0108-x. No abstract available.

PMID:
30291292
29.

A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily.

Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L; Cancer Genome Atlas Research Network, Weinstein JN, Mishra L, Akbani R.

Cell Syst. 2018 Oct 24;7(4):422-437.e7. doi: 10.1016/j.cels.2018.08.010. Epub 2018 Sep 26.

30.

Attenuation of YAP1 can potentially target cancer stem cells to overcome drug resistance.

Harada K, Song S, Ajani JA.

Oncoscience. 2018 Aug 22;5(7-8):214-215. doi: 10.18632/oncoscience.449. eCollection 2018 Jul. No abstract available.

31.

Serum miR-331-3p predicts tumor recurrence in esophageal adenocarcinoma.

Gu J, Zhang J, Zheng L, Ajani JA, Wu X, Ye Y.

Sci Rep. 2018 Sep 18;8(1):14006. doi: 10.1038/s41598-018-32282-9.

32.

Oesophageal preservation in locally advanced oesophageal cancer.

Ajani JA, Bhutani MS, Swisher SG.

Lancet Oncol. 2018 Sep;19(9):e430. doi: 10.1016/S1470-2045(18)30617-X. No abstract available.

PMID:
30191840
33.

Reply.

Song S, Ajani JA.

Gastroenterology. 2018 Sep;155(3):934-935. doi: 10.1053/j.gastro.2018.08.014. Epub 2018 Aug 10. No abstract available.

PMID:
30098926
34.

Surgeon Assessment of Gastric Cancer Lymph Node Specimens with a Video of Technique.

Ikoma N, Estrella JS, Hofstetter WL, Ajani JA, Fournier KF, Mansfield PF, Skibber JM, Badgwell BD.

J Gastrointest Surg. 2018 Nov;22(11):2013-2019. doi: 10.1007/s11605-018-3880-0. Epub 2018 Jul 27.

PMID:
30054780
35.

The ypT category does not impact overall survival in node negative gastric cancer.

Ikoma N, Hofstetter WL, Estrella JS, Das P, Minsky BD, Fournier KF, Mansfield PF, Ajani JA, Badgwell BD.

J Surg Oncol. 2018 Jun;117(8):1721-1728. doi: 10.1002/jso.25081. Epub 2018 Jun 27.

PMID:
29949666
36.

Potentially curable gastric adenocarcinoma treated without surgery.

Mizrak Kaya D, Nogueras-Gonzáles GM, Harada K, Amlashi FG, Thomas I, Rogers JE, Bhutani MS, Lee JH, Weston B, Minsky BD, Estrella JS, Blum Murphy MA, Matamoros A Jr, Devine CE, Das P, Badgwell BD, Ajani JA.

Eur J Cancer. 2018 Jul;98:23-29. doi: 10.1016/j.ejca.2018.04.012. Epub 2018 May 30.

PMID:
29859338
37.

Barrett's Esophagus after Bimodality Therapy in Patients with Esophageal Adenocarcinoma.

Amlashi FG, Wang X, Davila RE, Maru DM, Bhutani MS, Lee JH, Weston BR, Mizrak Kaya D, Vassilakopoulou M, Harada K, Blum Murphy MA, Rice DC, Hofstetter WL, Davila M, Nguyen QN, Ajani JA.

Oncology. 2018;95(2):81-90. doi: 10.1159/000488489. Epub 2018 May 29.

38.

Customization of therapy for gastroesophageal adenocarcinoma patients.

Mizrak Kaya D, Harada K, Amlashi FG, Vasilakopoulou M, Ajani JA.

Chronic Dis Transl Med. 2018 Mar 13;4(1):8-17. doi: 10.1016/j.cdtm.2018.02.003. eCollection 2018 Mar.

39.

Nodal Downstaging in Gastric Cancer Patients: Promising Survival if ypN0 is Achieved.

Ikoma N, Estrella JS, Hofstetter W, Das P, Minsky BD, Ajani JA, Fournier KF, Mansfield P, Badgwell BD.

Ann Surg Oncol. 2018 Jul;25(7):2012-2017. doi: 10.1245/s10434-018-6471-0. Epub 2018 May 10.

PMID:
29748883
40.

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade.

Shen J, Ju Z, Zhao W, Wang L, Peng Y, Ge Z, Nagel ZD, Zou J, Wang C, Kapoor P, Ma X, Ma D, Liang J, Song S, Liu J, Samson LD, Ajani JA, Li GM, Liang H, Shen X, Mills GB, Peng G.

Nat Med. 2018 May;24(5):556-562. doi: 10.1038/s41591-018-0012-z. Epub 2018 May 7.

41.

Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching.

Ikoma N, Das P, Hofstetter W, Ajani JA, Estrella JS, Chen HC, Wang X, Callender RA, Zhu C, Roland CL, Fournier KF, Cormier JN, Mansfield P, Badgwell BD.

Gastric Cancer. 2018 Nov;21(6):1004-1013. doi: 10.1007/s10120-018-0832-z. Epub 2018 May 5.

42.

Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives.

Taieb J, Moehler M, Boku N, Ajani JA, Yañez Ruiz E, Ryu MH, Guenther S, Chand V, Bang YJ.

Cancer Treat Rev. 2018 May;66:104-113. doi: 10.1016/j.ctrv.2018.04.004. Epub 2018 Apr 22. Review.

43.

Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype.

Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, Lee SH, Park JL, Park YY, Lee HS, Jang HJ, Park ES, Kim SC, Heo J, Chu IS, Jang YJ, Mok YJ, Jung W, Kim BH, Kim A, Cho JY, Lim JY, Hayashi Y, Song S, Elimova E, Estralla JS, Lee JH, Bhutani MS, Lu Y, Liu W, Lee J, Kang WK, Kim S, Noh SH, Mills GB, Kim SY, Ajani JA, Lee JS.

Nat Commun. 2018 May 3;9(1):1777. doi: 10.1038/s41467-018-04179-8.

44.

Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort.

Elimova E, Wang X, Qiao W, Sudo K, Wadhwa R, Shiozaki H, Shimodaira Y, Planjery V, Charalampakis N, Lee JH, Weston BR, Bhutani MS, Komaki R, Rice DC, Swisher SG, Blum MA, Rogers JE, Skinner HD, Maru DM, Hofstetter WL, Ajani JA.

Oncology. 2018;94(6):345-353. doi: 10.1159/000486720. Epub 2018 Apr 27.

45.

Personalized therapy based on image for esophageal or gastroesophageal junction adenocarcinoma.

Harada K, Mizrak Kaya D, Lopez A, Baba H, Ajani JA.

Ann Transl Med. 2018 Feb;6(4):80. doi: 10.21037/atm.2017.10.28. Review.

46.

Current therapeutic landscape for advanced gastroesophageal cancers.

Lopez A, Harada K, Mizrak Kaya D, Ajani JA.

Ann Transl Med. 2018 Feb;6(4):78. doi: 10.21037/atm.2017.10.29. Review.

47.

Immune checkpoint blockade therapy for esophageal squamous cell carcinoma.

Harada K, Mizrak Kaya D, Baba H, Ajani JA.

J Thorac Dis. 2018 Feb;10(2):699-702. doi: 10.21037/jtd.2018.01.120. No abstract available.

48.

Pyloroplasty may reduce weight loss 1 year after esophagectomy.

Harada K, Yoshida N, Baba Y, Nakamura K, Kosumi K, Ishimoto T, Iwatsuki M, Miyamoto Y, Sakamoto Y, Ajani JA, Watanabe M, Baba H.

Dis Esophagus. 2018 Mar 1;31(3). doi: 10.1093/dote/dox127.

PMID:
29579257
49.

Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006-2014.

Ikoma N, Cormier JN, Feig B, Du XL, Yamal JM, Hofstetter W, Das P, Ajani JA, Roland CL, Fournier K, Royal R, Mansfield P, Badgwell BD.

Cancer. 2018 Mar 1;124(5):998-1007. doi: 10.1002/cncr.31155. Epub 2018 Feb 2.

50.

Preoperative accuracy of gastric cancer staging in patient selection for preoperative therapy: race may affect accuracy of endoscopic ultrasonography.

Ikoma N, Lee JH, Bhutani MS, Ross WA, Weston B, Chiang YJ, Blum MA, Sagebiel T, Devine CE, Matamoros A Jr, Fournier K, Mansfield P, Ajani JA, Badgwell BD.

J Gastrointest Oncol. 2017 Dec;8(6):1009-1017. doi: 10.21037/jgo.2017.04.04.

Supplemental Content

Loading ...
Support Center